Generics US generics and specialty drugmaker Mylan (Nasdaq: MYL) says that its India based subsidiary, Mylan Pharmaceuticals (formerly Matrix Laboratories of which it acquired a 71% stake for around $736 million in 2007), has started commercial operations in India, initially with the launch of a comprehensive portfolio of 18 antiretroviral (ARV) products for the treatment of HIV/AIDS. India is home to the world's third largest population of people with HIV/AIDS, with approximately 2.4 million people living with the disease, of which fewer than 20% have access to treatment, the company noted. 7 August 2012